- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 278 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11. | ViroGates A/S - increase | 81 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 12.11. | ViroGates A/S - Observation status | 100 | GlobeNewswire | Nasdaq Copenhagen has today removed observation status for:
ISIN NAME
DK0061030574 VIROGATES
The company's observation status has been removed... ► Artikel lesen | |
| 12.11. | ViroGates A/S: suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates | 124 | GlobeNewswire (Europe) | Company Announcement no. 17/2025 (November 12, 2025)
BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the outcome of the public tender offer published on 8 October 2025 and on... ► Artikel lesen | |
| 06.11. | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2025 | 114 | GlobeNewswire (Europe) | Company Announcement no. 16/2025 (November 06, 2025)
Revenue rose 49% Y-o-Y in Q3, and total revenue for the first nine months is now slightly above the same period in 2024
BIRKERØD, DENMARK - ViroGates... ► Artikel lesen | |
| 08.10. | ViroGates A/S - Observation status | 142 | GlobeNewswire | Nasdaq Copenhagen has given the company below observation status:
ISIN DK0061030574 Symbol VIRO
ViroGates A/S has been given observation status, as the company has announced that suPAR... ► Artikel lesen | |
| 08.10. | ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium | 152 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company... ► Artikel lesen | |
| 21.08. | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 124 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen | |
| 16.06. | ViroGates A/S: ViroGates and GENSPEED achieve proof of concept for their suPARnostic POC+ targeted at the Longevity Testing Market | 207 | GlobeNewswire (Europe) | Company Announcement no. 9/2025 (June 16, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 21.05. | ViroGates A/S: Resolutions from the Extraordinary General Meeting of ViroGates A/S | 155 | GlobeNewswire (Europe) | Company Announcement no. 8/2025 (May 21, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 01.05. | ViroGates A/S: ViroGates announces its Q1 report for 2025 | 124 | GlobeNewswire (Europe) | Company Announcement no. 6/2025 (May 01, 2025)
Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 20.03. | ViroGates A/S: ViroGates announces its Annual Report 2024 | 222 | GlobeNewswire (Europe) | Company Announcement no. 3/2025 (March 20, 2025)
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships
BIRKERØD... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,54 | +0,27 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| POLYRIZON | 7,330 | 0,00 % | Polyrizon Ltd.: Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform | Ra'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,250 | +12,67 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| COGENT BIOSCIENCES | 38,980 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,820 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 22,020 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,150 | -3,90 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 40,405 | -1,42 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NUVALENT | 104,96 | -1,37 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,430 | -3,10 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| KYMERA THERAPEUTICS | 64,27 | -3,87 % | Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? | ||
| APOGEE THERAPEUTICS | 69,13 | +0,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | +1,44 % | Harmony Biosciences to present Dravet syndrome trial data at AES meeting | ||
| DISC MEDICINE | 89,72 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 178,96 | -3,03 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.